Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Investigational immunotherapy anti-PDL1 (MPDL3280A) shrank tumours in 43 percent of people with a specific type of metastatic bladder cancer in a Roche study
Investigational immunotherapy anti-PDL1 (MPDL3280A) shrank tumours in 43 percent of people with a specific type of metastatic bladder cancer in a Roche study
Investigational immunotherapy anti-PDL1 (MPDL3280A) shrank tumours in 43 percent of people with a specific type of metastatic bladder cancer in a Roche study
Submitted by
admin
on June 1, 2014 - 11:48am
Source:
Pipeline Review
News Tags:
MPDL3280A
Roche
bladder cancer
Headline:
Investigational immunotherapy anti-PDL1 (MPDL3280A) shrank tumours in 43 percent of people with a specific type of metastatic bladder cancer in a Roche study
Do Not Allow Advertisers to Use My Personal information
